What The Inflation Reduction Act’s Reforms To Medicare Part D Mean For Prescription Drug Prices

Anne Tumlinson foresees a benefit-offering slowdown in Medicare Advantage with a caveat in a discussion with Home Health Care News,

Anna Kaltenboeck writes in Bloomberg Law that Protecting Health Care for All Patients Act legislation would complicate efforts to lower drug prices in the U.S. and undermine Medicare’s new negotiating authority if the bill becomes law.

Anna Kaltenboeck discusses how the Centers for Medicare and Medicaid Services is preparing for prescription drug pricing negotiation with manufacturers with the Inflation Reduction Act now in place.